Kangchen Pharmaceutical announced that the first phase II clinical study of KC1086 tablets combined with fluvizil to treat HR+/HER2- locally advanced or metastatic breast cancer, developed independently by the company, has completed the first case of patients enrolled in group medication. KC1086 is a potent KAT6/7 dual-target small molecule inhibitor. Phase I clinical trials were initiated in August 2025, and obtained the acquiescence of clinical research on new drugs from the US FDA, making it the first KAT6/7 small molecule inhibitor in the world to enter clinical development.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.